Operationalizing diagnostic criteria for Alzheimer’s disease and other age‐related cognitive impairment—Part 2

التفاصيل البيبلوغرافية
العنوان:	Operationalizing diagnostic criteria for Alzheimer’s disease and other age‐related cognitive impairment—Part 2
المؤلفون:	Seshadri, Sudha, Beiser, Alexa, Au, Rhoda, Wolf, Philip A., Evans, Denis A., Wilson, Robert S., Petersen, Ronald C., Knopman, David S., Rocca, Walter A., Kawas, Claudia H., Corrada, Maria M., Plassman, Brenda L., Langa, Kenneth M., Chui, Helena C.
بيانات النشر:	American Psychiatric Association Wiley Periodicals, Inc.
سنة النشر:	2011
المجموعة:	University of Michigan: Deep Blue
مصطلحات موضوعية:	Alzheimer’s disease, Incidence, Prevalence, Population‐based, Diagnostic criteria, Cognitive impairment not dementia, Mild cognitive impairment, Dementia, Neurology and Neurosciences, Health Sciences
الوصف:	Peer Reviewed ; https://deepblue.lib.umich.edu/bitstream/2027.42/152578/1/alzjjalz201012002.pdfTest
نوع الوثيقة:	article in journal/newspaper
وصف الملف:	application/pdf
اللغة:	unknown
تدمد:	1552-5260 1552-5279
العلاقة:	Seshadri, Sudha; Beiser, Alexa; Au, Rhoda; Wolf, Philip A.; Evans, Denis A.; Wilson, Robert S.; Petersen, Ronald C.; Knopman, David S.; Rocca, Walter A.; Kawas, Claudia H.; Corrada, Maria M.; Plassman, Brenda L.; Langa, Kenneth M.; Chui, Helena C. (2011). "Operationalizing diagnostic criteria for Alzheimer’s disease and other age‐related cognitive impairment—Part 2." Alzheimer’s & Dementia 7(1): 35-52.; http://hdl.handle.net/2027.42/152578Test; Alzheimer’s & Dementia; RS Wilson, LA Beckett, DA Bennett, MS Albert, DA Evans. Change in cognitive function in older persons from a community population: relation to age and Alzheimer disease. Arch Neurol. 56: 1999; 1274 – 1279; R Gijsen, N Hoeymans, FG Schellevis, D Ruwaard, WA Satariano, GA van den Bos. Causes and consequences of comorbidity: a review. J Clin Epidemiol. 54: 2001; 661 – 674; KM Langa, BL Plassman, RB Wallace, AR Herzog, SG Heeringa, MB Ofstedal, et al. The Aging, Demographics, and Memory Study: study design and methods. Neuroepidemiology. 25: 2005; 181 – 191; RS Wilson, DR Weir, S Leurgans, DA Evans, LE Hebert, KM Langa, et al. Sources of variability in estimates of the prevalence of Alzheimer’s disease in the United States. Alzheimer Dement (in press).; American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM III). 1980; American Psychiatric Association: Washington, DC; H Petrovitch, GW Ross, Q He, J Uyehara‐Lock, W Markesbery, D Davis, et al. Characterization of Japanese‐American men with a single neocortical AD lesion type. Neurobiol Aging. 29: 2008; 1448 – 1455; R Mayeux, AM Saunders, S Shea, S Mirra, D Evans, AD Roses, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. Alzheimer’s Disease Centers Consortium on Apolipoprotein E and Alzheimer’s Disease. N Engl J Med. 338: 1998; 506 – 511, Erratum in: N Engl J Med 1998;338:1325; JA Schneider, NT Aggarwal, L Barnes, P Boyle, DA Bennett. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis. 18: 2009; 691 – 701; CL Meinert, S Tonascia. Clinical trials: design, conduct, and analysis. 1986; Oxford University Press: New York, NY; M Albert, LA Smith, PA Scherr, JO Taylor, DA Evans, HH Funkenstein. Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer’s disease. Int J Neurosci. 57: 1991; 167 – 178; GG Fillenbaum, CF Pieper, HJ Cohen, JC Cornoni‐Huntley, JM Guralnik. Comorbidity of five chronic health conditions in elderly community residents: determinants and impact on mortality. J Gerontol A Biol Sci Med Sci. 55: 2000; M84 – M89; G McKhann, D Drachman, M Folstein, R Katzman, D Price, EM Stadlan. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 34: 1984; 939 – 944; HC Chui, JI Victoroff, D Margolin, W Jagust, R Shankle, R Katzman, et al. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer’s Disease Diagnostic and Treatment Centers. Neurology. 42: 1992; 473 – 480; GC Roman, TK Tatemichi, T Erkinjuntti, JL Cummings, JC Masdeu, JH Garcia, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS‐AIREN International Workshop. Neurology. 43: 1993; 250 – 260; IG McKeith, EK Perry, RH Perry. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology. 53: 1999; 902 – 905; BL Miller, C Ikonte, M Ponton, M Levy, K Boone, A Darby, et al. A study of the Lund‐Manchester research criteria for frontotemporal dementia: clinical and single‐photon emission CT correlations. Neurology. 48: 1997; 937 – 942; RC Petersen, GE Smith, SC Waring, RJ Ivnik, EG Tangalos, E Kokmen. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 56: 1999; 303 – 308; B Winblad, K Palmer, M Kivipelto, V Jelic, L Fratiglioni, LO Wahlund, et al. Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 256: 2004; 240 – 246; MF Elias, A Beiser, PA Wolf, R Au, RF White, RB D’Agostino. The preclinical phase of Alzheimer disease: a 22‐year prospective study of the Framingham Cohort. Arch Neurol. 57: 2000; 808 – 813; DA Evans, HH Funkenstein, MS Albert, PA Scherr, NR Cook, MJ Chown, et al. Prevalence of Alzheimer’s disease in a community population of older persons. Higher than previously reported. JAMA. 262: 1989; 2551 – 2556; DA Evans, DA Bennett, RS Wilson, JL Bienias, MC Morris, PA Scherr, et al. Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol. 60: 2003; 185 – 189; RS Wilson, NT Aggarwal, LL Barnes, CF Mendes de Leon, LE Hebert, DA Evans. Cognitive decline in incident Alzheimer disease in a community population. Neurology. 74: 2010; 951 – 955; PJ Visser, F Verhey, DL Knol, P Scheltens, LO Wahlund, Y Freund‐Levi, et al. Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 8: 2009; 619 – 627; CR Jack Jr., DS Knopman, WJ Jagust, LM Shaw, PS Aisen, MW Weiner, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 9: 2010; 119 – 128; RC Petersen. Alzheimer’s disease: progress in prediction. The Lancet Neurology. 9: 2010; 4 – 5; RC Petersen, PS Aisen, LA Beckett, MC Donohue, AC Gamst, DJ Harvey, et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 74: 2010; 201 – 209; WJ Jagust, SM Landau, LM Shaw, JQ Trojanowski, RA Koeppe, EM Reiman, et al. Relationships between biomarkers in aging and dementia. Neurology. 73: 2009; 1193 – 1199; LM Shaw, H Vanderstichele, M Knapik‐Czajka, CM Clark, PS Aisen, RC Petersen, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 65: 2009; 403 – 413; GA Jicha, JE Parisi, DW Dickson, K Johnson, R Cha, RJ Ivnik, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 63: 2006; 674 – 681; RC Petersen, RO Roberts, DS Knopman, BF Boeve, YE Geda, RJ Ivnik, et al. Mild cognitive impairment: ten years later. Arch Neurol. 66: 2009; 1447 – 1455; C Kawas, S Gray, R Brookmeyer, J Fozard, A Zonderman. Age‐specific incidence rates of Alzheimer’s disease: the Baltimore Longitudinal Study of Aging. Neurology. 54: 2000; 2072 – 2077; R Brookmeyer, DA Evans, LA Hebert, KM Langa, SG Heeringa, BL Plassman, et al. National estimates of the prevalence of Alzheimer’s disease in the United States. Alzheimers Dement. 7: 2011; 61 – 73; TR Dawber, WB Kannel. The Framingham study. An epidemiological approach to coronary heart disease. Circulation. 34: 1966; 553 – 555; ME Farmer, LR White, SJ Kittner, E Kaplan, E Moes, P McNamara, et al. Neuropsychological test performance in Framingham: a descriptive study. Psychol Rep. 60: 1987; 1023 – 1040; MF Folstein, SE Folstein, PR McHugh. “Mini‐mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 12: 1975; 189 – 198; M Feinleib, WB Kannel, RJ Garrison, PM McNamara, WP Castelli. The Framingham Offspring Study. Design and preliminary data. Prev Med. 4: 1975; 518 – 525; DL Bachman, PA Wolf, RT Linn, JE Knoefel, JL Cobb, AJ Belanger, et al. Incidence of dementia and probable Alzheimer’s disease in a general population: the Framingham Study. Neurology. 43: 1993; 515 – 519; DL Bachman, PA Wolf, R Linn, JE Knoefel, J Cobb, A Belanger, et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology. 42: 1992; 115 – 119; A Beiser, RB D’Agostino Sr., S Seshadri, LM Sullivan, PA Wolf. Computing estimates of incidence, including lifetime risk: Alzheimer’s disease in the Framingham Study. The Practical Incidence Estimators (PIE) macro. Stat Med. 19: 2000; 1495 – 1522; S Seshadri, PA Wolf, A Beiser, R Au, K McNulty, R White, et al. Lifetime risk of dementia and Alzheimer’s disease. The impact of mortality on risk estimates in the Framingham Study. Neurology. 49: 1997; 1498 – 1504; S Seshadri, A Beiser, M Kelly‐Hayes, CS Kase, R Au, WB Kannel, et al. The lifetime risk of stroke: estimates from the Framingham Study. Stroke. 37: 2006; 345 – 350; S Seshadri, PA Wolf. Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study. Lancet Neurol. 6: 2007; 1106 – 1114; L Berg. Clinical dementia rating (CDR). Psychopharmacol Bull. 24: 1988; 637 – 639; American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders: DSM‐IV. 4th ed. 1994; American Psychiatric Association: Washington, DC; RO Roberts, YE Geda, DS Knopman, RH Cha, VS Pankratz, BF Boeve, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 30: 2008; 58 – 69; E Kokmen, CM Beard, KP Offord, LT Kurland. Prevalence of medically diagnosed dementia in a defined United States population: Rochester, Minnesota, January 1, 1975. Neurology. 39: 1989; 773 – 776; ZS Khachaturian. Diagnosis of Alzheimer’s disease: two‐decades of progress. J Alzheimers Dis. 9: 2006; 409 – 415; SS Mirra, A Heyman, D McKeel, SM Sumi, BJ Crain, LM Brownlee, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology. 41: 1991; 479 – 486; R Brookmeyer, S Gray, C Kawas. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 88: 1998; 1337 – 1342; DS Knopman, JE Parisi, A Salviati, M Floriach‐Robert, BF Boeve, RJ Ivnik, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 62: 2003; 1087 – 1095; DG Davis, FA Schmitt, DR Wekstein, WR Markesbery. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol. 58: 1999; 376 – 388; M Gearing, SS Mirra, JC Hedreen, SM Sumi, LA Hansen, A Heyman. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer’s disease. Neurology. 45: 1995; 461 – 466; JA Schneider, Z Arvanitakis, SE Leurgans, DA Bennett. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 66: 2009; 200 – 208; A Lim, D Tsuang, W Kukull, D Nochlin, J Leverenz, W McCormick, et al. Clinico‐neuropathological correlation of Alzheimer’s disease in a community‐based case series. J Am Geriatr Soc. 47: 1999; 564 – 569; MD Ikonomovic, WE Klunk, EE Abrahamson, CA Mathis, JC Price, ND Tsopelas, et al. Post‐mortem correlates of in vivo PiB‐PET amyloid imaging in a typical case of Alzheimer’s disease. Brain. 131: 2008; 1630 – 1645; WE Klunk, H Engler, A Nordberg, Y Wang, G Blomqvist, DP Holt, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound‐B. Ann Neurol. 55: 2004; 306 – 319; A Okello, J Koivunen, P Edison, HA Archer, FE Turkheimer, K Nagren, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C‐PIB PET study. Neurology. 73: 2009; 754 – 760; RC Petersen, RO Roberts, DS Knopman, YE Geda, RH Cha, VS Pankratz, et al. Prevalence of mild cognitive impairment is higher in men: the Mayo Clinic Study of Aging. Neurology. 75: 2010; 889 – 897; M Lorenzi, M Donohue, D Paternico, C Scarpazza, S Ostrowitzki, O Blin, et al. Enrichment through biomarkers in clinical trials of Alzheimer’s drugs in patients with mild cognitive impairment. Neurobiol Aging. 31: 2010; 1443 – 1451, 1451 e1; G Blessed, BE Tomlinson, M Roth. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 114: 1968; 797 – 811; American Psychiatric Association American Psychiatric Association Work Group to Revise DSM‐III Diagnostic and Statistical Manual of Mental Disorders: DSM‐III‐R. 3rd ed. 1987; American Psychiatric Association: Washington, DC; LE Hebert, PA Scherr, LA Beckett, MS Albert, DM Pilgrim, MJ Chown, et al. Age‐specific incidence of Alzheimer’s disease in a community population. JAMA. 273: 1995; 1354 – 1359; R Katzman, M Aronson, P Fuld, C Kawas, T Brown, H Morgenstern, et al. Development of dementing illnesses in an 80‐year‐old volunteer cohort. Ann Neurol. 25: 1989; 317 – 324; C Eisdorfer, D Cohen. Diagnostic criteria for primary neuronal degeneration of the Alzheimer’s type. J Fam Pract. 11: 1980; 553 – 557; MM Corrada, R Brookmeyer, D Berlau, A Paganini‐Hill, CH Kawas. Prevalence of dementia after age 90: results from the 90+ study. Neurology. 71: 2008; 337 – 343; MM Corrada, R Brookmeyer, A Paganini‐Hill, D Berlau, CH Kawas. Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann Neurol. 67: 2010; 114 – 121; DJ Berlau, MM Corrada, E Head, CH Kawas. APOE ɛ2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology. 72: 2009; 829 – 834; HA Crystal, D Dickson, P Davies, D Masur, E Grober, RB Lipton. The relative frequency of “dementia of unknown etiology” increases with age and is nearly 50% in nonagenarians. Arch Neurol. 57: 2000; 713 – 719; GM Savva, SB Wharton, PG Ince, G Forster, FE Matthews, C Brayne, et al. Age, neuropathology, and dementia. N Engl J Med. 360: 2009; 2302 – 2309; R Mayeux, C Reitz, AM Brickman, MN Haan, JJ Manly, MM Glymour, et al. Operationalizing diagnostic criteria for Alzheimer’s disease and other age‐related cognitive impairment—Part 1. Alzheimers Dement. 7: 2011; 15 – 34; BL Plassman, RJ Havlik, DC Steffens, MJ Helms, TN Newman, D Drosdick, et al. Documented head injury in early adulthood and risk of Alzheimer’s disease and other dementias. Neurology. 55: 2000; 1158 – 1166; JC Breitner, KA Welsh, BA Gau, WM McDonald, DC Steffens, AM Saunders, et al. Alzheimer’s disease in the National Academy of Sciences‐National Research Council Registry of Aging Twin Veterans. III. Detection of cases, longitudinal results, and observations on twin concordance. Arch Neurol. 52: 1995; 763 – 771; JC Breitner, BW Wyse, JC Anthony, KA Welsh‐Bohmer, DC Steffens, MC Norton, et al. APOE‐epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology. 53: 1999; 321 – 331; BL Plassman, DC Steffens, JR Burke, KA Welsh‐Bohmer, TN Newman, D Drosdick, et al. Duke Twins Study of Memory in Aging in the NAS‐NRC Twin Registry. Twin Res Hum Genet. 9: 2006; 950 – 957; BL Plassman, AS Khachaturian, JJ Townsend, MJ Ball, DC Steffens, CE Leslie, et al. Comparison of clinical and neuropathologic diagnoses of Alzheimer’s disease in 3 epidemiologic samples. Alzheimers Dement. 2: 2006; 2 – 11; F Massoud, G Devi, Y Stern, A Lawton, JE Goldman, Y Liu, et al. A clinicopathological comparison of community‐based and clinic‐based cohorts of patients with dementia. Arch Neurol. 56: 1999; 1368 – 1373; FE Matthews, BC Stephan, IG McKeith, J Bond, C Brayne. Medical Research Council Cognitive Function and Ageing Study. Two‐year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?. J Am Geriatr Soc. 56: 2008; 1424 – 1433
DOI:	10.1016/j.jalz.2010.12.002
الإتاحة:	https://doi.org/10.1016/j.jalz.2010.12.002Test http://hdl.handle.net/2027.42/152578Test
حقوق:	IndexNoFollow
رقم الانضمام:	edsbas.9C310A4C
قاعدة البيانات:	BASE

View record in BASE

Full Text Finder

الوصف
تدمد:	15525260 15525279
DOI:	10.1016/j.jalz.2010.12.002